Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is curative for a variety of malignant hematological diseases that are traditionally poorly responsive to standard therapies. Allo-HCT is effective because of the donor vs. host alloimmune responses that occur following transplantation.   These alloimmune responses are driven by donor T cells and are so potent that they can potentially eradicate chemotherapy refractory leukemia [1–3] However, donor T cells can also recognize recipient tissues and mount an immunological attack resulting in graft vs.

Source: Biology of Blood and Marrow Transplantation - June 22, 2021 Category: Hematology Authors: Logan G. Spector, Stephen R. Spellman, Bharat Thyagarajan, Kenneth B. Beckman, Cody Hoffmann, John Garbe, Theresa Hahn, Lara Sucheston-Campbell, Michaela Richardson, Todd E. De For, Jakub Tolar, Michael R. Verneris Source Type: research